Welcome to our dedicated page for Igm Biosciences SEC filings (Ticker: IGMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Baffled by 200-page biotech reports? IGM Biosciences’ filings weave complex immunology, trial data and funding details that can slow even seasoned analysts. Our platform distills every IGM Biosciences SEC filing so you can focus on decisions, not deciphering.
Stock Titan’s AI reviews each submission the moment it hits EDGAR, turning raw disclosures into plain-English highlights. Whether you need the latest IGM Biosciences quarterly earnings report 10-Q filing to gauge cash runway or want IGM Biosciences insider trading Form 4 transactions before market open, we surface the essentials in seconds.
Here’s how we simplify biotech due diligence:
- Real-time alerts on IGM Biosciences Form 4 insider transactions so you never miss executive stock moves
- AI-powered summaries of the annual report – think IGM Biosciences annual report 10-K simplified – highlighting R&D expense trends and pivotal trial timelines
- Side-by-side comparisons of successive 10-Qs for quick IGM Biosciences earnings report filing analysis
- Plain-language explanations of 8-K material events, collaboration amendments, and shelf registrations – IGM Biosciences 8-K material events explained
- Proxy statement insights that unpack IGM Biosciences executive compensation without legal jargon
Need deeper context? Our expert commentary answers natural questions such as “understanding IGM Biosciences SEC documents with AI” and “where to find IGM Biosciences executive stock transactions Form 4.” From pre-clinical pipeline shifts to partnership revenue recognition, every disclosure is tagged, summarized and cross-linked for effortless navigation.
Stop combing through footnotes. See the story behind every filing, updated in real time and explained simply.
IGM Biosciences (IGMS) Principal Accounting Officer Steven Weber reported a sale of 486 shares of common stock on June 16, 2025. The transaction was executed at a weighted average price of $1.1992 per share, with individual trades ranging from $1.17 to $1.22.
Key details of the transaction:
- The sale was specifically conducted to cover tax withholding obligations related to the vesting of restricted stock units
- Following the transaction, Weber maintains direct beneficial ownership of 26,530 shares
- The Form 4 was filed on June 28, 2025, with signature by power of attorney through Misbah Tahir
This transaction represents a routine share sale for tax purposes rather than a discretionary trading decision by the insider. The relatively small transaction size and its purpose suggest minimal significance for investor sentiment.
FAQ
What is the current stock price of Igm Biosciences (IGMS)?
What is the market cap of Igm Biosciences (IGMS)?
